Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA) – a phase 2a randomized placebo-controlled trial
Maher et al.
www.thelancet.com/respiratory Published online May 20, 2018
Categorised in: Publication / May 28, 2018 12:45 pm /Tags: IPF
A randomized study using FRI to characterize bronchodilator effects of glycopyrrolate formoterol fumarate delivered by a metered dose inhaler using co-suspension delivery technology in patients with COPD>